TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06798012: A Phase 2, Open-label, Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of TAK-411 in Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (The CASCA Study)

Sponsor: Takeda · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$465,600

Rescue Site Savings

+$310,400

Unlock Full NCT06798012 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06798012 Rescue Dossier →